Status:
UNKNOWN
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis
Lead Sponsor:
I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Conditions:
Primary Osteosarcoma of Bone
Eligibility:
All Genders
Brief Summary
The aim of this project is to test a new powerful PNA-based SENP1 inhibitor, previously characterized in an in vitro model of OS cell lines. The most effective PNA, conjugated with a cell-permeable C...
Detailed Description
Background: Osteosarcoma (OS) is the most common type of primary malignant bone tumor in children and adolescents. The overall survival rate is dramatically reduced by the development of metastases, ...
Eligibility Criteria
Inclusion
- Indication for primary OS eradication surgery
- Patients hospitalized in Istituto Ortopedico Galeazzi
- Patients with age ≥18 years: were/can be recruited within the IRCCS Istituto Ortopedico Galeazzi BioBanca (ethical committee approval n. 29/INT/2017).
- Patients with age \<18 years: will be additionally recruited besides the IRCCS Istituto Ortopedico Galeazzi BioBanca.
Exclusion
- Patients not able to sign the Informed Consent.
Key Trial Info
Start Date :
January 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT03798587
Start Date
January 1 2020
End Date
December 1 2021
Last Update
November 22 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IRCCS Istituto Ortopedico Galeazzi
Milan, Italy, 20161